Home / About Novasep / Media & Events / Press releases

Press releases

Novasep appoints two executives to further strengthen its management team

05 May 2015

Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director


Novasep reports strong 2014 full year results

21 Apr 2015


- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy


Novasep and Celladon Execute MYDICAR API supply agreement

24 Mar 2015

Pompey, France, and San Diego, CA, USA, March 24, 2015 - Novasep, a leading supplier of services and technologies for the life sciences and chemical industries and Celladon Corporation (Nasdaq:CLDN), a clinical-stage cardiovascular gene therapy company, today announce that they have signed a Development, Manufacturing and Supply Agreement pursuant to which, if supported by upcoming MYDICAR clinical data, Novasep would manufacture MYDICAR drug substance through 2018 with extension options through 2020.


Novasep selected to commercially biomanufacture Celladon’s Mydicar API

17 Feb 2015

Novasep, a leading supplier of services and technologies for the life sciences industry, today announces that it has entered into an agreement with Celladon, a clinical-stage biotechnology company. Novasep will prepare to supply the drug substance for MYDICAR®.


Novasep opens new office in Thailand

15 Dec 2014

Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.


Novasep and partner Nilsan Nishotech to install the first continuous chromatography system at Laurus Labs

13 Nov 2014

Novasep Varicol high-performance continuous chromatography technology brings productivity gains in an Indian-based API commercial production.



Novasep passes FDA inspections on two sites

22 Jul 2014

Novasep wins approval to produce new molecular entity for US market.


Novasep-MIE consortium to construct the first sorbitol production plant in Vietnam

17 Jun 2014

The plant will enable Vietnam to domestically produce sorbitol, a sugar substitute it currently imports.


Novasep’s EUR 4 million plant extension for commercial ADC payload manufacturing now commissioned

15 May 2014

The new Highly Potent API (HPAPI) manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.


You can continue visiting and select more documents or directly download the one you selected.